Repeat Potassium Before Withholding Perindopril
The perindopril should NOT be withheld based on this single hemolyzed potassium result of 5.5 mmol/L. The laboratory explicitly noted the sample was hemolyzed, which commonly causes falsely elevated potassium readings, and this patient has preserved renal function (eGFR 73 mL/min/1.73m²) making true severe hyperkalemia less likely.
Immediate Action Required
Repeat the potassium measurement immediately using a non-hemolyzed sample before making any medication changes. This is critical because:
- Hemolysis releases intracellular potassium into serum, artificially elevating the measured value
- The patient's eGFR of 73 mL/min/1.73m² represents only mild renal impairment
- True hyperkalemia >5.5 mmol/L occurs in only 6.4% of ACE inhibitor-treated patients 1
If True Hyperkalemia is Confirmed (K+ ≥5.5 mmol/L)
Should the repeat potassium confirm elevation ≥5.5 mmol/L, then address reversible factors before discontinuing perindopril:
Step 1: Identify and Remove Potassium-Raising Factors 1
- Discontinue potassium supplements if prescribed
- Stop potassium-sparing diuretics (spironolactone, amiloride, triamterene)
- Eliminate NSAIDs (including over-the-counter ibuprofen, naproxen)
- Reduce dietary potassium intake (bananas, oranges, tomatoes, salt substitutes)
Step 2: Assess Volume Status
- Check for dehydration or excessive diuretic use
- Ensure adequate salt and fluid intake 2
Step 3: Monitor and Adjust
If potassium remains 5.5-6.0 mmol/L after removing aggravating factors:
- Continue perindopril with close monitoring (recheck potassium in 1-2 weeks) 1
- Consider adding a thiazide or loop diuretic, which reduces hyperkalemia risk by approximately 60% 2
Only discontinue perindopril if:
- Potassium exceeds 6.0 mmol/L 1
- Hyperkalemia persists despite removing all aggravating factors
- Patient develops symptoms of hyperkalemia (muscle weakness, cardiac arrhythmias)
Monitoring Protocol for This 81-Year-Old Patient
Given her age and mild renal impairment, establish this monitoring schedule 3:
Initial monitoring (first 2 months):
- Potassium and creatinine at 1-2 weeks after any dose change 1
- Then monthly for the first 2-3 months
Ongoing monitoring:
- Potassium and creatinine every 3-6 months once stable 4
- More frequent monitoring if intercurrent illness, dehydration, or new medications
Expected Creatinine Changes
An increase in creatinine up to 30% above baseline within the first 2-4 weeks is expected and acceptable with ACE inhibitors in patients with baseline renal impairment 2, 5. This hemodynamic effect:
- Typically stabilizes after 4 weeks
- Is associated with long-term renoprotection and slowing of kidney disease progression
- Should NOT prompt discontinuation unless the increase exceeds 30% 2, 5
For this patient with baseline creatinine of 68 µmol/L, an increase up to approximately 88 µmol/L would be acceptable.
Dosing Considerations for Elderly Patients
At age 81, this patient should follow the elderly dosing protocol 3:
- Start at 2 mg once daily for week 1
- Increase to 4 mg once daily for week 2
- Target maintenance dose of 8 mg once daily if tolerated
- Monitor blood pressure for orthostatic hypotension (measure supine and after 1-3 minutes standing) 6
Critical Pitfalls to Avoid
- Do not discontinue ACE inhibitors based on hemolyzed potassium results - always repeat
- Do not stop therapy for creatinine increases <30% within the first 2 months 2, 5
- Do not overlook NSAIDs as a common cause of hyperkalemia in elderly patients 1
- Do not assume high-risk patients are being monitored - only 10% of patients receive guideline-recommended monitoring 7
- Do not use angiotensin receptor blockers as substitutes during acute kidney injury or severe hyperkalemia 1
The evidence strongly supports continuing ACE inhibitor therapy even when acute creatinine increases occur, as long-term outcomes (cardiovascular events, nephropathy progression, mortality) are improved regardless of initial creatinine rise 5. The cardioprotective and renoprotective benefits of perindopril are maintained even in patients with mild-moderate renal insufficiency (eGFR >30 mL/min/1.73m²) 8.